Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research

Staurosporine: new lease of life for parent compound of today’s novel and highly successful anti-cancer drugs

(2018) Satoshi Ōmura et al.   JOURNAL OF ANTIBIOTICS

Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril

(2017) Fedor Simko et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations

(2017) Andy Crump   JOURNAL OF ANTIBIOTICS

The Proteasome Inhibition Model of Parkinson’s Disease

(2017) Eduard Bentea et al.   Journal of Parkinsons Disease

Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson’s disease in young and adult mouse

(2017) Mari H. Savolainen et al.   EXPERIMENTAL BRAIN RESEARCH

KCTD5 and Ubiquitin Proteasome Signaling Are Required for Helicobacter pylori Adherence

(2017) Alhejandra Álvarez et al.   Frontiers in Cellular and Infection Microbiology

HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma

(2017) Aimée N. Laporte et al.   PLoS One

Melatonin, bone regulation and the ubiquitin-proteasome connection: A review

(2016) Jerry Vriend et al.   LIFE SCIENCES

Structure- and function-based design of Plasmodium-selective proteasome inhibitors

(2016) Hao Li et al.   NATURE

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

(2016) Shilpi Khare et al.   NATURE

Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate

(2016) Ian F. Harrison et al.   NEUROSCIENCE LETTERS

The ubiquitin-proteasome system is essential for the productive entry of Japanese encephalitis virus

(2016) Shaobo Wang et al.   VIROLOGY

p62 at the crossroad of the ubiquitin-proteasome system and autophagy

(2016) Victoria Cohen-Kaplan et al.   Oncotarget

Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: Comparison to the classical neurotoxin 6-OHDA

(2015) Jolanta Konieczny et al.   BEHAVIOURAL BRAIN RESEARCH

Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer

(2015) A. Mehta et al.   ENDOCRINE-RELATED CANCER

The proteasome inhibitor lactacystin enhances GSH synthesis capacity by increased expression of antioxidant components in an Nrf2-independent, but p38 MAPK-dependent manner in rat colorectal carcinoma cells

(2015) Nils-Erik Huseby et al.   FREE RADICAL RESEARCH

Effect of cisplatin on proteasome activity

(2015) G.R. Tundo et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Parkinson's disease

(2015) Lorraine V Kalia et al.   LANCET

The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases

(2014) Isabel Saez et al.   CURRENT GENOMICS

Proteasome inhibitor lactacystin enhances cisplatin cytotoxicity by increasing endoplasmic reticulum stress-associated apoptosis in HeLa cells

(2014) YE XU et al.   Molecular Medicine Reports

Investigation the mechanism of the apoptosis induced by lactacystin in gastric cancer cells

(2014) Yinghua Li et al.   TUMOR BIOLOGY

Chronic l-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra

(2013) Jolanta Konieczny et al.   BEHAVIOURAL BRAIN RESEARCH

Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: Behavior, positron emission tomography, immunohistochemistry

(2013) Scott Mackey et al.   EXPERIMENTAL NEUROLOGY

Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases

(2013) Yuichi Honma et al.   JOURNAL OF GASTROENTEROLOGY

The proteasome inhibitor lactacystin exerts its therapeutic effects on glioma via apoptosis: An in vitro and in vivo study

(2013) Haifeng Wang et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Blocking Plasmodium falciparum Development via Dual Inhibition of Hemoglobin Degradation and the Ubiquitin Proteasome System by MG132

(2013) Rajesh Prasad et al.   PLoS One

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

(2012) Y. H. Messinger et al.   BLOOD

Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells

(2012) Denis Selimovic et al.   CELLULAR SIGNALLING

Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling

(2012) Alfeu Zanotto-Filho et al.   INVESTIGATIONAL NEW DRUGS

Glucocorticoid and proteasome inhibitor impact on the leukemic lymphoblast: Multiple, diverse signals converging on a few key downstream regulators

(2012) George I. Lambrou et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Parkinson's Disease: Genetics and Pathogenesis

(2011) Joshua M. Shulman et al.   Annual Review of Pathology-Mechanisms of Disease

Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates

(2011) Timothy J. Collier et al.   NATURE REVIEWS NEUROSCIENCE

Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats

(2011) Elżbieta Lorenc-Koci et al.   NEUROCHEMISTRY INTERNATIONAL

ABT-737 synergizes with Bortezomib to kill melanoma cells

(2011) S. N. Reuland et al.   Biology Open

Proteasome inhibitors: Dozens of molecules and still counting

(2010) Geoffroy de Bettignies et al.   BIOCHIMIE

Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease

(2010) Anthony C Vernon et al.   BMC NEUROSCIENCE

Effect of Proteasome Inhibitors With Different Chemical Structures on the Ubiquitin–Proteasome System In Vitro

(2010) V. Csizmadia et al.   VETERINARY PATHOLOGY

The Proteasome Inhibitor Epoxomicin Has Potent Plasmodium falciparum Gametocytocidal Activity

(2009) B. Czesny et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The proteasomal system

(2009) Tobias Jung et al.   MOLECULAR ASPECTS OF MEDICINE

The proteasome: Overview of structure and functions

(2009) Keiji TANAKA   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Nigral Degeneration with Inclusion Body Formation and Behavioral Changes in Rats after Proteasomal Inhibition

(2009) Chaoshi Niu et al.   STEREOTACTIC AND FUNCTIONAL NEUROSURGERY

Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines

(2008) A. Sorolla et al.   BRITISH JOURNAL OF DERMATOLOGY

Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon

(2008) Andrea Kreidenweiss et al.   MALARIA JOURNAL

Marine Actinomycetes: A New Source of Compounds against the Human Malaria Parasite

(2008) Jacques Prudhomme et al.   PLoS One

Proteasome inhibitors: Poisons and remedies

(2007) Silke Meiners et al.   MEDICINAL RESEARCH REVIEWS